Victor Strasburg, MD
Family Medicine · Pierre, SDNPI 1346860467
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations.
Across 81 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$281
- Amgen$247
- Pfizer$193
- Medtronic$113
- Novartis$94
- Vertex$65
- plus $415 from 15 others
What the payments were for
- Food & beverage$1,408100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 18 | $281 |
| Amgen | 16 | $247 |
| Pfizer | 12 | $193 |
| Medtronic | 2 | $113 |
| Novartis | 4 | $94 |
| Vertex | 4 | $65 |
| Exact Sciences | 4 | $60 |
| Boehringer Ingelheim | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| AbbVie | 2 | $36 |
| AstraZeneca | 2 | $35 |
| Boston Scientific | 1 | $31 |
| Novo Nordisk | 2 | $30 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| Axonics, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $15 |
| Merck | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Solventum Corporation | 1 | $14 |
How this compares
$1,408 in reported general payments places this provider in the 85th percentile of 408 family medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $57,797 |
| EliquisApixaban | 38 | $50,084 |
| JardianceEmpagliflozin | 45 | $45,677 |
| XareltoRivaroxaban | 32 | $23,045 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $16,271 |
| JanuviaSitagliptin Phosphate | 11 | $15,462 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $13,982 |
| MyrbetriqMirabegron | 28 | $13,268 |
| FarxigaDapagliflozin Propanediol | 12 | $9,577 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $6,875 |
| Repatha SureclickEvolocumab | 11 | $5,809 |
| TradjentaLinagliptin | 12 | $4,922 |
| VascepaIcosapent Ethyl | 13 | $4,253 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 18 | $3,757 |
| Valsartan | 118 | $3,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $30 | $57,79761 claims |
| Boehringer IngelheimJardiance, Tradjenta | $52 | $50,59957 claims |
| PfizerEliquis | $193 | $50,08438 claims |
| MerckJanuvia, Janumet | $15 | $22,33724 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $13,26828 claims |
| AstraZenecaFarxiga | $35 | $9,57712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 408 family medicine providers in South Dakota.
Other family medicine in Pierre
- Jenna WickershamPierre$4K
- Michael RichardsonPierre$3K
- Kyla Helm-SwansonRapid City$22K
- Andrew BurchettSioux Falls$13K
- Lornell HansenSioux Falls$11K
- Michael GerlachMitchell$9K
- Jeffry MeyerSioux Falls$8K
- Scott BoyensSioux Falls$6K
- Terry GraberCuster$6K
- Christi ChildersSpearfish$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.